NAD+ and Weight Loss: Does It Really Work?

The studies discussed here do not establish NAD+ as a weight-loss treatment. A change in a metabolic marker is not the same as a demonstrated weight-loss benefit.

This guide discusses oral supplementation research. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are NAD+ precursors; they are different substances from NAD+ itself. Findings cannot be transferred automatically between ingredients, doses or routes, including injections and infusions.

Does NAD+ Help You Lose Weight?

The evidence reviewed below does not justify expecting weight loss from a product sold as NAD+ or recommending it alongside a GLP-1 medication for better results. This is a limited evidence appraisal, not an exhaustive review proving that no relevant studies exist.

How NAD+ Relates to Metabolism

NAD+ participates in cellular metabolism. That biological role alone does not establish that supplementation causes fat loss or improves an individual’s energy. Research must test the actual ingredient and outcome; marketing terms such as metabolic support do not specify a demonstrated clinical benefit.

What the Evidence Shows

A 2020 randomized crossover trial of oral NR compared six weeks of supplementation with placebo in 13 adults with overweight or obesity. The full report describes changes in fat-free and fat-mass percentages, but no change in total body weight. It found no improvement in insulin sensitivity or muscle mitochondrial function.

The authors caution that they tested many outcomes without adjusting for multiple comparisons, so some positive findings could be due to chance. Fat-free mass percentage does not by itself establish muscle gain. These findings do not demonstrate a weight-loss treatment or benefit from combining NR with a GLP-1 medication.

A 2021 randomized NMN trial followed 25 postmenopausal women with overweight or obesity and prediabetes for ten weeks. Muscle insulin sensitivity improved, while fat mass, fat-free mass and other measured body-composition outcomes did not change. Liver and adipose-tissue insulin sensitivity also did not improve.

That muscle insulin finding is distinct from weight loss. The small, short study does not establish lasting clinical benefit, long-term safety or outcomes in other populations. Neither trial studied NAD+ itself, injections or an added GLP-1 treatment.

Foundations of Weight Management

Discuss nutrition, activity, medical history and appropriate treatment options with your clinician. Do not replace prescribed care with an NAD-related product on the strength of metabolic claims.

For a separate discussion of combination evidence, see NAD+ alongside GLP-1 medications. This link is not a recommendation to add a supplement.

Realistic Expectations

• Identify the exact ingredient, formulation and route.
• Ask whether a study measured weight loss, body composition or a metabolic marker.
• Do not assume a short study establishes long-term benefit or safety.
• Review supplements and medicines together with your clinician.

Bottom Line

The evidence assessed here does not establish a weight-loss benefit for an unspecified NAD+ product or added benefit alongside GLP-1 treatment. Discuss the exact product and your goals with your clinician.

Explore compounded tirzepatide — not FDA-approved

Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. NAD+ supplements are not FDA-approved drugs. This article is educational and is not medical advice. Consult your own clinician before starting any supplement. Individual results vary.